Exploratory experiment designed to discover new patterns targeting Nrf2 in RAW264.7 cells and/or mouse model. Primary outcome: blocking of acteoside's anti-ferroptotic action
This experiment used ML385, a specific Nrf2 inhibitor, to validate that acteoside's anti-ferroptotic effects are mediated through Nrf2 activation. The study involved treating cells with acteoside in the presence of ML385 to demonstrate that blocking Nrf2 signaling would prevent acteoside's protective effects against ferroptosis. This pharmacological approach provided direct evidence that the Nrf2 pathway is essential for acteoside's mechanism of action. The experiment confirmed that acteoside's anti-ferroptotic and protective effects in SALI depend on Nrf2 activation, establishing a clear mechanistic link between the compound, the transcription factor, and the cellular death pathway.
co-treatment with acteoside and ML385, assessment of ferroptosis markers
ML385 blocks acteoside's anti-ferroptotic effects
loss of acteoside's anti-ferroptotic activity when Nrf2 is inhibited
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.